Literature DB >> 24958972

Effectiveness evaluation of a pharmacist-driven monitoring database for tardive dyskinesia.

Lauren A Diefenderfer1, Leigh Anne Nelson2, Ellie Elliott1, Yifei Liu3, Courtney Iuppa1, Elizabeth Winans3, Roger W Sommi2.   

Abstract

BACKGROUND: Tardive dyskinesia (TD) is a potentially irreversible, chronic syndrome related to antipsychotic medication use characterized by hyperkinetic abnormal involuntary movements. Various studies have shown that development of TD is possible with both first- and second-generation antipsychotics. Regular monitoring for emergence of TD symptoms is recommended in clinical practice for early recognition and intervention.
METHODS: This is a retrospective, single-center, observational study of the effectiveness of a pharmacist-driven monitoring database for TD assessment. Subjects were adult inpatients at a state psychiatric hospital who received antipsychotic treatment for at least 3 or 6 months between January 2006 and December 2011. The primary objective was to assess compliance rates with TD monitoring based on facility policy before and after implementation of the database at 3 and 6 months following initiation of antipsychotic therapy.
RESULTS: A significant improvement in compliance with TD monitoring policy was seen after implementation of the database (2.9% vs 66.7%; P < .001). Compliance with TD monitoring did not differ between classes of antipsychotic medication, hospital units, or age groups.
CONCLUSION: The results of this study demonstrate that pharmacists can help improve compliance with TD assessment and that monitoring databases may be useful for similar extended or long-term care settings to ensure timely assessment of patients for the development or progression of TD.

Entities:  

Keywords:  antipsychotics; monitoring; tardive dyskinesia

Year:  2014        PMID: 24958972      PMCID: PMC4062734          DOI: 10.1310/hpj4906-544

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  10 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

2.  How to examine patients using the Abnormal Involuntary Movement Scale.

Authors:  M R Munetz; S Benjamin
Journal:  Hosp Community Psychiatry       Date:  1988-11

3.  Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.

Authors:  Michael J Peluso; Shôn W Lewis; Thomas R E Barnes; Peter B Jones
Journal:  Br J Psychiatry       Date:  2012-03-22       Impact factor: 9.319

Review 4.  The current status of tardive dyskinesia.

Authors:  P S Sachdev
Journal:  Aust N Z J Psychiatry       Date:  2000-06       Impact factor: 5.744

5.  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Authors:  Scott W Woods; Hal Morgenstern; John R Saksa; Barbara C Walsh; Michelle C Sullivan; Roy Money; Keith A Hawkins; Ralitza V Gueorguieva; William M Glazer
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

6.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

Authors:  S Leucht; G Pitschel-Walz; D Abraham; W Kissling
Journal:  Schizophr Res       Date:  1999-01-04       Impact factor: 4.939

Review 7.  Physical health monitoring of patients with schizophrenia.

Authors:  Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

Review 8.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

9.  Reliability, validity, and a total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations.

Authors:  R L Sprague; J E Kalachnik
Journal:  Psychopharmacol Bull       Date:  1991

10.  Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale.

Authors:  R D Lane; W M Glazer; T E Hansen; W H Berman; S I Kramer
Journal:  J Nerv Ment Dis       Date:  1985-06       Impact factor: 2.254

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.